Get ready to energize your life?
Top Offers Only Today
Support your health and step-up your mental focus
post in: Beauty, News Date:22 Nov 2017, 16:24 views:868
1.2.1 Smoking cessation An up-to-date smoking history, including pack years with smoked (number of cigarettes smoked per day, divided by 20, multiplied by the asthma number of years smoked should be documented for everyone with copd. 2004 All copd patents still smoking, regardless of age, should be encouraged to stop, and offered help to do so, at every opportunity. 2004 Unless contraindicated, offer NRT, varenicline or bupropion, as appropriate, to people who are planning to stop smoking combined with an appropriate support programme to optimise smoking quit rates for people with copd.
2010, the following two recommendations are from '. Varenicline for smoking cessation ' (nice technology appraisal guidance 123).
Varenicline is recommended within its licensed indications as an option for smokers who have expressed a desire to quit smoking. 2007 Varenicline should normally be prescribed only as part of a programme of behavioural support.
2007.2.2 Inhaled therapy, short-acting beta2 agonists (saba) and short-acting muscarinic antagonists (sama) Short-acting bronchodilators, as necessary, should be the initial empirical treatment for the relief of breathlessness and exercise limitation. 2004, inhaled corticosteroids Oral corticosteroid reversibility tests do not predict response to inhaled corticosteroid therapy and should not be used to identify which patients should be prescribed inhaled corticosteroids. 2004 Be aware of the potential risk of developing side effects (including non-fatal pneumonia) in people with copd treated with inhaled corticosteroids and be prepared to discuss with patients.
New 2010, inhaled combination therapy. This section test provides recommendations on the sequence of inhaled therapies for people with stable copd.
These recommendations are also given in diagram form in algorithm 2a (see appendix C). The effectiveness of bronchodilator therapy should not be assessed by lung function alone but should include a variety of other measures such as improvement in symptoms, activities of daily living, exercise capacity, and rapidity of symptom relief.
2004 Offer once-daily long-acting muscarinic antagonist (lama) in preference to four-times-daily short-acting muscarinic antagonist (sama) to people with stable copd who remain breathless or have exacerbations despite using short-acting bronchodilators as required, and in whom a decision has been made to commence regular maintenance bronchodilator.